R. A., Neeraj J. Agrawal, H. Kumar
Sep 1, 2018
Citations
1
Influential Citations
11
Citations
Quality indicators
Journal
Life Sciences
Abstract
ABSTRACT The increased prevalence of cardio‐metabolic disorders worldwide prompted the exploration of new strategies for its treatment. Peroxisome Proliferator activated receptor (PPAR) play major role in regulation of lipid as well as glucose metabolism and thus, natural PPAR&ggr; activators seem to be drug of choice. Aims: In the present work, we studied norbixin which is a natural apocarotenoid derivative for its agonistic activity for PPAR &ggr; followed by in vivo studies for amelioration of cardio‐metabolic syndrome (CMetS). Main methods: The methods include computational studies, TR‐FRET binding analysis and in vivo studies on high fat diet induced rats. Key findings: Molecular docking and molecular dynamics (MD) simulation studies showed that norbixin could be embedded into hydrophobic pocket of PPAR&ggr; and stable hydrogen bonding interactions were found with residues Glu273, Tyr327, Ser289, His323, His449 and Tyr473 of PPAR&ggr;. These results were substantiated by significant in vitro PPAR agonistic activity of norbixin in TR‐FRET binding assay studies. The experimental results of norbixin in high fat diet induced CMetS in rats further confirmed that norbixin decreased insulin resistance (IR), hyperglycemia and dyslipidemia. These results were accompanied by reduced inflammatory marker hs‐CRP as well as decreased oxidative stress and arterial pressure. The histopathology of heart sections also showed that norbixin could prevent the abnormal fibrotic changes in heart. Furthermore, PPAR&ggr; protein expressions were increased, whereas NF‐&kgr;B expression was decreased by norbixin treatment in western blot studies. Significance: These results validate norbixin as a novel PPAR&ggr; agonist and prove therapeutic potential of norbixin in treatment of CMetS. Graphical abstract Figure. No caption available.